Climb Bio to Present Budoprutug Data at ASH
Climb Bio will share safety and B-cell depletion data from a Phase 1b trial of budoprutug in immune thrombocytopenia at the 68th ASH Annual Meeting.
Updated on Nov. 4, 2026 in Biotech
Climb Bio, Inc. (Nasdaq: CLYM) will present preliminary clinical data for budoprutug, a novel anti-CD19 monoclonal antibody, in previously treated adults with primary immune thrombocytopenia at the 68th American Society of Hematology Annual Meeting on December 12-15, 2026, in New Orleans. The presentation will include safety, B-cell depletion, and platelet data from all three dose cohorts of the ongoing Phase 1b trial.
Why it matters
The data will give the medical community its first look at how budoprutug performs across the trial's dose cohorts in immune thrombocytopenia. Budoprutug has also received Orphan Drug and Fast Track Designations from the FDA for primary membranous nephropathy, making the ASH readout a key checkpoint for the program.
The presentation covers three dose cohorts from the ongoing Phase 1b trial, with poster 3003 in Session 311 at the ASH meeting. Results are preliminary, and the detailed outcome figures are not yet public.
The players
Climb Bio, Inc.
Climb Bio is a clinical-stage biotechnology company listed on Nasdaq under the symbol CLYM and headquartered in Wellesley Hills, Massachusetts.
American Society of Hematology
The American Society of Hematology is the professional organization for blood specialists that hosts the annual ASH meeting, one of the largest hematology conferences in the world.
The details
Budoprutug targets and depletes CD19-expressing B cells, including plasmablasts and certain plasma cells, and is engineered with enhanced effector function and low picomolar affinity. The poster is titled 'Budoprutug, a low-fucosylated anti-CD19 monoclonal antibody, in adults with primary immune thrombocytopenia: Preliminary phase 1b study results.'
Timeline
Climb Bio announces its ASH data presentation on November 4, 2026.
The budoprutug poster presentation is scheduled for December 13, 2026, from 6:00 to 8:00 pm CT.
The 68th ASH Annual Meeting runs December 12-15, 2026, in New Orleans.
Roadmap
Budoprutug's CD19-targeting approach places Climb Bio among developers pursuing B-cell depletion as a treatment strategy for autoimmune blood and kidney diseases. Its FDA Fast Track and Orphan Drug designations for membranous nephropathy show regulators are considering the program in a second indication alongside immune thrombocytopenia.
For people living with primary immune thrombocytopenia, the data may signal whether budoprutug could become a future treatment option that targets the B cells involved in the disease. A subcutaneous formulation is in development, which could eventually make the therapy easier to access outside clinical settings.
The takeaway
Early trial readouts like this one are the first real signal of whether a therapy will advance, so the December ASH data is worth watching for patients and investors tracking immune-mediated blood disorders. Readers should keep an eye on the full outcome figures once they are published in December.
What happens next
Climb Bio's budoprutug poster presentation at the ASH Annual Meeting is scheduled for December 13, 2026, from 6:00 to 8:00 pm CT in New Orleans.
Further reading
For broader context on drug development pipelines, explore our Biotech coverage.
